Yahoo
NasdaqCM - Delayed Quote USD

Dianthus Therapeutics, Inc. (DNTH)

82.49 +0.60 (+0.73%)
At close: June 18 at 4:00:00 PM EDT
82.88 +0.39 (+0.47%)
After hours: June 18 at 6:23:55 PM EDT
Trade DNTH on Coinbase
Chart Range Bar
Loading chart for DNTH
  • Previous Close 81.89
  • Open 83.64
  • Bid 60.16 x 200
  • Ask 102.65 x 200
  • Day's Range 79.79 - 84.82
  • 52 Week Range 16.64 - 96.50
  • Volume 2,478,036
  • Avg. Volume 852,155
  • Market Cap (intraday) 4.509B
  • Beta (5Y Monthly) 0.07
  • PE Ratio (TTM) --
  • EPS (TTM) -4.23
  • Earnings Date May 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 127.67

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

dianthustx.com

92

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DNTH
100.17%
S&P 500 (^GSPC)
9.57%

1-Year Return

DNTH
372.99%
S&P 500 (^GSPC)
25.41%

3-Year Return

DNTH
681.16%
S&P 500 (^GSPC)
70.10%

5-Year Return

DNTH
52.26%
S&P 500 (^GSPC)
80.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 463k
Earnings -40.83M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-60M
-40M
-20M
0

Analyst Insights

View More

Analyst Price Targets

98.00
127.67 Average
82.49 Current
200.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/6/2026
Analyst Wedbush
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 103 -> 105

Statistics

View More

Valuation Measures

Annual
As of 6/18/2026
  • Market Cap

    4.51B

  • Enterprise Value

    3.40B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.57k

  • Price/Book (mrq)

    3.75

  • Enterprise Value/Revenue

    2.54k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -14.99%

  • Return on Equity (ttm)

    -22.70%

  • Revenue (ttm)

    1.34M

  • Net Income Avi to Common (ttm)

    -173.66M

  • Diluted EPS (ttm)

    -4.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.11B

  • Total Debt/Equity (mrq)

    0.11%

  • Levered Free Cash Flow (ttm)

    -71.03M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

82.49 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: